Honestly, I have to disagree with the current information. It is just like that - ‘I have an idea to find a medicine to cure a disease’, but it is at the very beginning of the exploration of research.
The idea of VDP-156 is kind of a startup project that involves not only basic research, compound synthesis, and clinical trials, but also marketing, selling, distribution, etc.
In terms of business, 50,000$ may be not still enough to last to the marketing stage.
More evidence or information is needed for me to support the idea.
This idea requires more context. Are we talking about a BAT (bioactive therapy) containing supplements like creatine, glycine, theanine, possibly vitamin C, calcium, and magnesium? A single powder formulation that could potentially be sold in the future? If so, part of the funds could go into the Treasury and potentially be distributed among token holders, maybe with an annual standard allocation of free shipments.
By “longevity mix,” I mean something like what Bryan Johnson or various companies offer—standard powdered blends of bioactive compounds designed to be taken with a glass of water in the morning. There is existing research on ingredients that might contribute to longevity, so a typical morning powder could be a good fit for VitaDAO’s merchandise.
A clearer distribution model would be needed—either selling the product and directing part of the revenue to the Treasury or offering token holders certain benefits, such as two free shipments per year, to test the concept. Given VitaDAO’s growing community, this could be an interesting opportunity. If the supplement is well-formulated with proven ingredients—like creatine, NAC, ginger, curcumin, and other effective combos—there’s no reason why people wouldn’t want to buy it.
Starting a supplement company might be a good idea, but it requires more context. In principle, I don’t see why not. The community is expanding, and if a mechanism is in place to offer benefits from sales (such as free baseline supplement kits for token holders), the concept of a longevity cocktail becomes clearer and more compelling.
I’m not sure if $50,000 would be enough for full-scale development, but it could be enough to test a single product.